Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Thyroid Eye Disease
Interventions: AMG 732, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: Little Rock, Arkansas • Newport Beach, California • Jacksonville, Florida + 9 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Dolutegravir, Prednisone; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: HER2 Positive Solid Tumors
Interventions: SBT6050, pembrolizumab, Cemiplimab; Drug
Lead sponsor: Silverback Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Boston, Massachusetts • Durham, North Carolina • Pittsburgh, Pennsylvania + 3 more

Conditions: Pruritus
Interventions: Obeticholic acid, Linerixibat; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
Interventions: Vodobatinib (K0706) capsules; Drug
Lead sponsor: Sun Pharma Advanced Research Company Limited; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 8
States / cities: Downey, California • Los Angeles, California • Jacksonville, Florida + 5 more

Conditions: Healthy Volunteer
Interventions: CC-92480; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma
Interventions: Diagnostic Mammography, Resection, Ultrasound Imaging, Twinkling Marker Placement; Procedure · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prosthesis User, Amputation, Upper Limb Amputation at the Wrist, Upper Limb Amputation Above Elbow (Injury), Upper Limb Amputation Below Elbow (Injury)
Interventions: Qualitative Analysis; Other
Lead sponsor: Louis Stokes VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 178 participants
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Carcinoma
Interventions: Survey Administration, Tomato-Soy Juice; Other · Dietary Supplement
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Anxiety, Infertility, Female
Interventions: In-person yoga for fertility group, Online yoga for fertility group, In person discussion only group; Behavioral
Lead sponsor: Fertility Centers of Illinois; Other
Eligibility: 24 Years to 42 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Eating Behavior, Obesity, Satiation
Interventions: portion or unportioned food; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Suicide, Attempted, Suicidal Ideation
Interventions: Brief Cognitive Behavioral Therapy (BCBT), Present-Centered Therapy (PCT), Treatment as Usual (TAU); Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Jacksonville, North Carolina • Columbus, Ohio • Charleston, South Carolina

Conditions: Autism Spectrum Disorder
Interventions: Wide-spectrum nutritional supplement, Placebo; Drug · Other
Lead sponsor: Rossignol Medical Center; Other
Eligibility: 2 Years to 17 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Prostate Cancer
Interventions: Mindfulness-based Intervention, Usual Care; Behavioral
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Gaucher Disease
Interventions: Digital Engagement Application (GD App), No Intervention; Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Treatment Refusal
Interventions: BEAST, Descriptive Feedback; Behavioral
Lead sponsor: University of Southern Mississippi; Other
Eligibility: 18 Years to 65 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Hattiesburg, Mississippi

Conditions: Myeloproliferative Neoplasms of, Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis
Interventions: LY2784544; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 9
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 6 more

Conditions: Hemostasis
Interventions: Fibrin Pad, SURGICEL™; Drug · Device
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 11
States / cities: Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 6 more

Conditions: Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Advanced Colorectal Carcinoma, Advanced Colorectal Adenocarcinoma
Interventions: VS-6766/avutometinib, Cetuximab, Pill Diary; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pregnancy, Stress, Psychological, Stress, Physiological, Maternal-fetal Relations
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1,506 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2022
U.S. locations: 4
States / cities: Philadelphia, Pennsylvania

Conditions: Non Small Cell Lung Cancer
Interventions: DZD6008, Sunvozertinib; Drug
Lead sponsor: Dizal Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: New York, New York • Fairfax, Virginia

Conditions: Aging, Longevity, Biomarkers of Aging
Interventions: Psilocybin (Usona Institute); Drug
Lead sponsor: Charles Raison; Other
Eligibility: 60 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Edwards, Colorado

Conditions: Metastatic Solid Tumors
Interventions: SLR-108, SLX-1411; Drug
Lead sponsor: Solve Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Squamous NSCLC
Interventions: CV09070101 mRNA vaccine (CVHNLC) 50 µg, CV09070101 mRNA vaccine (CVHNLC) 100 µg, CV09070101 mRNA vaccine (CVHNLC) 200 µg, CV09070101 mRNA vaccine (CVHNLC) 400 µg; Biological
Lead sponsor: CureVac; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Fairfax, Virginia • Richmond, Virginia

Search by objective public record fields.

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

Drug Interaction Study Between Dolutegravir and Prednisone

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants

Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy Subjects

An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast Cancer, The UTMOST2 Trial

Evaluating the Experience of Upper Limb Prosthesis Use

Taste Acceptability of Tomato-Soy-Arugula Seed Beverages in Men With Prostate Cancer

Stress and Fertility: How to Lower Stress When Trying to Conceive

Liking of Snack Foods - Sub-Study 1

Brief Cognitive Behavioral Therapy Replication Trial

Effect of a Wide Spectrum Nutritional Supplement on Mitochondrial Function in Children With Autism Spectrum Disorder

Testing the Effect of Mindfulness for Prostatectomy Outcomes

A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy

Behavioral Economics Intervention to Increase Treatment Seeking in the National Guard

Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms

The Fibrin Patch Soft Tissue Study

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

Happy Mommy! Happy Baby! Study

A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life

SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors

Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)